Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
33%
Ph phase_2
2
33%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(1)
Other(3)

Detailed Status

unknown3
Not yet recruiting1
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

not_yet_recruiting117%
recruiting117%
unknown350%
completed117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_1

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

NCT05909436
completedphase_1

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

NCT03713905
not_yet_recruitingphase_3

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

NCT05798819
unknownphase_3

GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

NCT05518318
unknownphase_2

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

NCT03655483
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05909436Phase 1

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Recruiting
NCT03713905Phase 1

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Completed
NCT05798819Phase 3

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Not Yet Recruiting
NCT05518318Phase 3

GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Unknown
NCT03655483Phase 2

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Unknown
NCT03972722Phase 2

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6